Indapamide 2.5 mg Tablets – Summary of Product Characteristics (SmPC) for healthcare professionals

1 NAME OF THE MEDICINAL PRODUCT

Indapamide 2.5 mg Tablets

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Indapamide 2.5mg

Excipient(s) with known effect

Lactose

Sucrose

For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Co

ate

d

tab

let

White, biconvex, sugar coated tablet

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

For the treatment of essential hypertension

4.2 Posology and method of administration

Posology

Adults:

The dosage is one tablet, containing 2.5mg indapamide, to be taken daily in the morning. The action of indapamide is progressive and the reduction in blood pressure may continue and not reach a maximum until several months after the start of therapy. A larger dose than 2.5mg of indapamide daily is not recommended as there is no appreciable additional anti-hypertensive effect but a diuretic effect may become apparent. If a single daily tablet of indapamide does not achieve a sufficient reduction in blood pressure, another anti- hypertensive agent may be added; those which have been used in combination with indapamide include beta-blockers, ACE inhibitors, methyldopa, clonidine and other adrenergic blocking agents.

The co-administration of indapamide with diuretics which may cause hypokalaemia is not recommended.

There is no evidence of rebound hypertension on withdrawal of indapamide.

Special populations

Renal failure (see sections 4.3 and 4.4):

In severe renal failure (creatinine clearance below 30ml/min), treatment is contraindicated.

Thiazides and related diuretics are fully effective only when renal function is normal or only minimally impaired.

Hepatic impairment (see sections 4.3 and 4.4):

In severe hepatic impairment, treatment is contraindicated.

Elderly (see section 4.4):

In the elderly, the plasma creatinine must be adjusted in relation to age, weight and gender. Elderly patients can be treated with indapamide when renal function is normal or only minimally impaired.

Paediatric population:

Indapamide is not recommended for use in children and adolescents due to a lack of data on safety and efficacy.

Method administration

Oral use.

4.3 Contraindications

Hypersensitivity to the active substance, or to other sulfonamides, or to any of the excipients listed in section 6.1.

Severe renal failure

Hepatic encephalopathy or severe impairment of liver function

Hypokalaemia

Porphyria

Addison’s disease

Refractory hypokalaemia, hyponatraemia, hypercalcaemia

4.4 Special warnings and precautions for use

Special warnings

When liver function is impaired, thiazide-related diuretics may cause hepatic encephalopathy, which can progress to hepatic coma particularly in case of electrolyte imbalance. Administration of the diuretic must be stopped immediately if this occurs or there are signs of increasing renal insufficiency.

A slight weight loss has been reported in some patients taking indapamide.

Photo

sensit

ivity

Cases of photosensitivity reactions have been reported with thiazides and thiazide-related diuretics (see section 4.8). If a photosensitivity reaction occurs during treatment, it is recommended to stop the treatment. If a re-administration of the diuretic is deemed necessary, it is recommended to protect exposed areas from the sun or artificial UVA.

Choroidal effusion, acute myopia and secondary angle-closure glaucoma:

Sulfonamide or sulfonamide derivative drugs can cause an idiosyncratic reaction resulting in choroidal effusion with visual field defect, transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue drug intake as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy

Excipients

This product contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

This product contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

Special precautions for use:

• Water and

electrolyte balance:

Plas

ma

sodiu

m

This must be measured before starting treatment, then at regular intervals subsequently. The fall in plasma sodium may be asymptomatic initially and regular monitoring is therefore essential and should be even more frequent in the elderly and cirrhotic patients (see sections 4.8 and 4.9). Any diuretic treatment may cause hyponatraemia, sometimes with very serious consequences. Hyponatraemia with hypovolaemia may be responsible for dehydration and orthostatic hypotension. Concomitant loss of chloride ions may lead to secondary compensatory metabolic alkalosis: the incidence and degree of this effect are slight.

Plasma

potassiu

m

Potassium depletion with hypokalaemia is the major risk of thiazide and related diuretics. H y p o k a l a e m i a m a y c a u s e m u s c l e d i s o r d e r s . C a s e s o f R h a b d o m yo l y s i s h a v e b e e n r e p o r t e d , m a i n l y i n t h e c o n t e x t o f s e v e r e h y p o k a l a e m i a . The risk of onset of hypokalaemia (<3.4mmol/l) must be prevented in certain high-risk populations, i.e. the elderly, malnourished and/or polymedicated, patients with hyperaldosteronism, cirrhotic patients with oedema and ascites, coronary artery disease and cardiac failure patients. In this situation, hypokalaemia increases the cardiac toxicity of digitalis preparations and the risks of arrhythmias.

Individuals with a long QT interval are also at risk, whether the origin is congenital or iatrogenic. Hypokalaemia, as well as bradycardia, is then a predisposing factor to the onset of severe arrhythmias, in particular, potentially fatal torsades de pointes.

More frequent monitoring of plasma potassium is required in all the situations indicated above. The first measurement of plasma potassium should be obtained during the first week following the start of treatment. Detection of hypokalaemia requires its correction. Hypokalaemia found in association with low serum magnesium concentration can be refractory to treatment unless serum magnesium is corrected.

Plasma magnesium:

Thiazides and related diuretics including indapamide have been shown to increase the urinary excretion of magnesium, which may result in hypomagnesaemia (see section 4.5 and 4.8).

Plasm

a

calciu

m

Thiazide and related diuretics may decrease urinary calcium excretion and cause a slight and transitory rise in plasma calcium. Frank hypercalcaemia may be due to previously unrecognised hyperparathyroidism.

Treatment should be withdrawn before the investigation of parathyroid function.

Blood

glucos

e

Monitoring of blood glucose is important in diabetics, in particular in the presence of hypokalaemia.

U

r

i

c

a

c

i

d

Tendency to gout attacks may be increased in

hyperuricaemic patients.

Renal function and

diuretics

Thiazide and related diuretics are fully effective only when renal function is normal or only minimally impaired (plasma creatinine below levels of the order of 25mg/l, i.e. 220μmol/l in an adult). In the elderly, this plasma creatinine must be adjusted in relation to age, weight and gender.

Hypovolaemia, secondary to the loss of water and sodium induced by the diuretic at the start of treatment causes a reduction in glomerular filtration. This may lead to an increase in blood urea and plasma creatinine. This transitory functional renal insufficiency is of no consequence in individuals with normal renal function but may worsen pre-existing renal insufficiency. Use with caution in patients with nephrotic syndrome.

A

t

h

l

e

t

e

s

The attention of athletes is drawn to the fact that this

medicinal product contains an active ingredient which may give a positive reaction in doping tests.

Indapamide may cause exacerbation of systemic lupus erythematosus.

4.5 Interaction with other medicinal products and other forms of

interaction

Combinations that are not recommended

Lithium:

Increased plasma lithium with signs of overdosage, as with a salt-free diet (decreased urinary lithium excretion). However, if the use of diuretics is necessary, careful monitoring of plasma lithium and dose adjustment are required.

Combinations requiring precautions

for use

Torsade de pointes-inducing drugs such as but not limited to:

• class Ia antiarrhythmics (quinidine, hydroquinidine, disopyramide)
• class III antiarrhythmics (amiodarone, sotalol, dofetilide, ibutilide, bretylium)

• some antipsychotics:

  • phenothiazines (chlorpromazine, cyamenazine, levomepromazine, thioridazine, trifluoperazine),
  • benzamides (amisulpride, sulpiride, sultopride tiapride),
  • butyrophenones (droperidol, haloperidol)
  • other antipsychotics (e.g. pimozide),
• Others: bepridil, cisapride, diphemanil, erythromycin IV, halofantrine, mizolastine, pentamidine, sparfloxacin, moxifloxacin, vincamine IV, methadone, astemizole, terfenadine.

Increased risk of ventricular arrhythmias, particularly torsades de pointes (hypokalaemia is a risk factor).

Monitor for hypokalaemia and correct, if required, before introducing this combination. Clinical, plasma electrolytes and ECG monitoring. Use substances which do not have the disadvantage of causing torsades de pointes in the presence of hypokalaemia.

NSAIDs (systemic route) including COX-2 selective inhibitors, high dose salicylic acid (≥ 3 g/day):

Possible reduction in the antihypertensive effect of indapamide.

Risk of acute renal failure in dehydrated patients (decreased glomerular filtration).

Hydrate the patient; monitor renal function at the start of treatment.

Angiotensin converting enzyme (ACE) inhibitors:

Risk of sudden hypotension and/or acute renal failure when treatment with an ACE inhibitor is initiated in the presence of pre-existing sodium depletion (particularly in patients with renal artery stenosis).

In hypertension, when prior diuretic treatment may have caused sodium depletion, it is necessary:

• either to stop the diuretic 3 days before starting treatment with the ACE inhibitor, and restart a hypokalaemic diuretic if necessary;
• or give low initial doses of the ACE inhibitor and increase only gradually.

In congestive heart failure, start with a very low dose of ACE inhibitor, possibly after a reduction in the dose of the concomitant hypokalaemic diuretic.

In all cases, monitor renal function (plasma creatinine) during the first weeks of treatment with an ACE inhibitor.

Other compounds causing hypokalaemia: amphotericin B (IV), gluco- and mineralocorticoids (systemic route), tetracosactide, stimulant laxatives:

Increased risk of hypokalaemia (additive effect).

Monitoring of plasma potassium and correction if required. Must be particularly borne in mind in case of concomitant digitalis treatment. Use non-stimulant laxatives.

Baclofen:

Increased antihypertensive effect.

Hydrate the patient; monitor renal function at the start of treatment.

Digitalis preparations:

Hypokalaemia and/or hypomagnesaemia predisposing predispose to the toxic effects of digitalis.

Monitoring of plasma potassium, magnesium and ECG and, if necessary, adjust the treatment.

Combinations requiring special care:

Allopurinol:

Concomitant treatment with indapamide may increase the incidence of hypersensitivity reactions to allopurinol.

Combinations which must be taken into

consideration:

Potassium-sparing diuretics (amiloride, spironolactone, triamterene):

Whilst rational combinations are useful in some patients, hypokalaemia or hyperkalaemia particularly in patients with renal failure or diabetes may still occur.

Plasma potassium and ECG should be monitored and, if necessary, treatment reviewed.

Metformin:

Increased risk of metformin induced lactic acidosis due to the possibility of functional renal failure associated with diuretics and more particularly with loop diuretics. Do not use metformin when plasma creatinine exceeds 15mg/l (135μmol/l) in men and 12mg/l (110μmol/l) in women.

Iodinated contrast media:

In the presence of dehydration caused by diuretics, increased risk of acute renal failure, in particular when large doses of iodinated contrast media are used. Rehydration before administration of the iodinated compound.

Imipramine-like antidepressants, neuroleptics:

Antihypertensive effect and increased risk of orthostatic hypotension increased

(additive effect).

Calcium (salts):

Risk of hypercalcaemia resulting from decreased urinary elimination of calcium.

Ciclosporin,

tacrolimus:

Risk of increased plasma creatinine without any change in circulation ciclosporin levels, even in the absence of water/sodium depletion.

Corticosteroids, tetracosactide (systemic route):

Decreased antihypertensive effect (water/sodium retention due to corticosteroids).

4.6 Fertility, pregnancy and lactation

P

r

e

g

n

a

n

c

y

There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of indapamide in pregnant women. Prolonged exposure to thiazide during the third trimester of pregnancy can reduce maternal plasma volume as well as uteroplacental blood flow, which may cause a foeto-placental ischaemia and growth retardation.

Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).

As a precautionary measure, it is preferable to avoid the use of indapamide during pregnancy.

Bre

ast-

feed

ing

Indapamide is excreted in human milk in small amounts.Hypersensitivity to sulfonamide-derived medicines and hypokalaemia might occur. A risk to the newborns/infants cannot be excluded. Indapamide is closely related to thiazide diuretics which have been associated, during breast-feeding, with decreased or even suppression of milk lactation.

Indapamide should not be used during breast-feeding.

Fertility

Reproductive toxicity studies showed no effect on fertility in female and male rats (see section 5.3). No effects on human fertility are anticipated.

4.7 Effects on ability to drive and use machines

Indapamide does not affect vigilance but different reactions in relation with the decrease in blood pressure may occur in individual cases, especially at the start of the treatment or when another antihypertensive agent is added. As a result the ability to drive or to operate machinery may be impaired.

4.8 Undesirable effects

Summary of safety profile

The most commonly reported adverse reactions are hypokalaemia, hypersensitivity reactions, mainly dermatological, in subjects with a predisposition to allergic and asthmatic reactions and maculopapular rashes.

Tabulated summary of adverse reactions

The following undesirable effects have been observed with indapamide during treatment ranked under the following frequency: Very common ( 1/10), common ( 1/100 and < 1/10), uncommon ( 1/1,000 and < 1/100), rare ( 1/10,000 and < 1/1,000), very rare (< 1/10,000) and frequency not known (cannot be estimated from the data available).

Description of selected adverse reactions

During phase II and III studies comparing indapamide 1.5mg and 2.5mg, plasma potassium analysis showed a dose-dependent effect of indapamide:

• Indapamide 1.5mg: Plasma potassium <3.4 mmol/l was seen in 10 % of patients and < 3.2 mmol/l in 4 % of patients after 4 to 6 weeks treatment. After 12 weeks treatment, the mean fall in plasma potassium was 0.23 mmol/l.
• Indapamide 2.5 mg:- Plasma potassium <3.4 mmol/l was seen in 25 % of patients and < 3.2 mmol/l in 10 % of patients after 4 to 6 weeks treatment. After 12 weeks treatment, the mean fall in plasma potassium was 0.41 mmol/l. Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme; website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

Symptoms

Indapamide has been found free of toxicity at up to 40 mg, i.e. 16 times the therapeutic dose.

Signs of acute poisoning take the form above all of water/electrolyte disturbances (hyponatraemia, hypokalaemia). Clinically, possibility of nausea, vomiting, hypotension, cramps, vertigo, drowsiness, confusion, polyuria or oliguria possibly to the point of anuria (by hypovolaemia).

Management

Initial measures involve the rapid elimination of the ingested substance(s) by gastric wash-out and/or administration of activated charcoal, followed by restoration of water/electrolyte balance to normal in a specialised centre.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Sulfonamides, plain, ATC code: C03BA11.

Mechanism of action

Indapamide is a non-thiazide sulfonamide with an indole ring, belonging to the diuretic family. At the dose of 2.5 mg per day indapamide exerts a prolonged antihypertensive activity in hypertensive human subjects.

Pharmacodynamic effects

Dose-effect studies have demonstrated that, at the dose of 2.5 mg per day, the antihypertensive effect is maximal and the diuretic effect is of mild intensity. At this antihypertensive dose of 2.5 mg per day, indapamide reduces vascular hyperreactivity to noradrenaline in hypertensive patients and decreases total peripheral resistance and arteriolar resistance.

The implication of an extrarenal mechanism of action in the antihypertensive effect is demonstrated by maintenance of its antihypertensive efficacy in functionally anephric hypertensive patients.

The vascular mechanism of action of indapamide involves:

• a reduction in the contractility of vascular smooth muscle due to a modification of transmembrane ion exchanges, essentially calcium;

• vasodilatation due to stimulation of the synthesis of prostaglandin

  PGE2 and the vasodilator and platelet antiaggregant prostacyclin PGI2;

• potentiation of the vasodilator action of bradykinin.

It has also been demonstrated that in the short-, medium- and long-term, in hypertensive patients, indapamide:

• reduces left ventricular hypertrophy;
• does not appear to alter lipid metabolism: triglycerides, LDL-cholesterol and HDL-cholesterol;
• does not appear to alter glucose metabolism, even in diabetic hypertensive patients. Normalisation of blood pressure and a significant reduction in microalbuminuria have been observed after prolonged administration of indapamide in diabetic hypertensive subjects.

Lastly, the co-prescription of indapamide with other antihypertensives (betablockers, calcium channel blockers, angiotensin converting enzyme inhibitors) results in an improved control of hypertension with an increased percentage of responders compared to that observed with single-agent therapy.

5.2 Pharmacokinetic properties

Absorption

Indapamide is rapidly and completely absorbed after oral administration. Peak blood levels are obtained after 1 or 2 hours.

Distribution

Indapamide is concentrated in the erythrocytes and is 79% bound to plasma protein and to erythrocytes. It is taken up by the vascular wall in smooth vascular muscle according to its high lipid solubility.

Metabolism

70% of a single oral dose is eliminated by the kidneys and 23% by the gastrointestinal tract. Indapamide is metabolised to a marked degree with 7% of the unchanged product found in the urine during the 48 hours following administration. Elimination half-life (β phase) of indapamide is approximately 15 – 18 hours.

5.3 Preclinical safety data

Indapamide has been tested negative concerning mutagenic and carcinogenic properties.

The highest doses administered orally to different animal species (40 to 8000 times the therapeutic dose) have shown an exacerbation of the diuretic properties of indapamide. The major symptoms of poisoning during acute toxicity studies with indapamide administered intravenously or intraperitoneally were related to the pharmacological action of indapamide, i.e. bradypnoea and peripheral vasodilation.

Reproductive toxicity studies have not shown embryotoxicity and teratogenicity. Fertility was not impaired either in male or in female rats.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Lactose

Maize Starch

Polyvidone

Magnesium Stearate

Seal coat:

Opaseal (Polyvinylacetate Phthalate, Ethyl Acetate and Stearic Acid)

Purified Talc

Subcoat:

Calcium Carbonate

Acacia

Titanium Dioxide (E171)

Purified Talc

Sucrose

Smoothing Syrup:

Sucrose

Colour Coat:

Sucrose

Titanium Dioxide (E171)

Smoothing Syrup:

Sucrose

Polishing Coat:

Opaglos 6000P (Shellac, Carnauba Wax Yellow and Beeswax White)

6.2 Incompatibilities

None stated

6.3 Shelf life

Blister Packs - 4 years

Polypropylene tablet containers – 3 years

6.4 Special precautions for storage

Tablet containers: Do not store above 25°C. Keep the container tightly closed.

Blisters: Do not store above 25ºC. Store in the original package.

6.5 Nature and contents of container

1. 1. Polypropylene tablet containers with low density polyethylene caps. High density polyethylene film may be used as packing material.

Pack sizes: 28, 30, 50, 56, 60, 100, 120 and 250 tablets

1. 2. Blister packs consisting of clear PVC and hard temper aluminium foil contained in a carton.

Pack sizes 28, 30, 50, 56, 60, 100 and 120 tablets

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

None stated.

7 MARKETING AUTHORISATION HOLDER

Strides Pharma UK Ltd

Unit 4, The Metro Centre,

Dwight Road, Watford,

WD18 9SS

United Kingdom

8 MARKETING AUTHORISATION NUMBER(S)

PL 13606/0118

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE

AUTHORISATION

10/03/2025

10 DATE OF REVISION OF THE TEXT

02/04/2026